Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha

Authors not listed

National Center for Research Resources (NCRR)

Abstract

In this phase I-II parallel design, randomized, double-blind clinical trial we will determine if 3,000 or 30,000 units ingested hrIFN-a prevents deterioration of cognitive functioning in patients with dementia of Alzheimer's type (AD) and whether ingested hrIFN-a treatment decreases acute phase reactants and pro-inflammatory cytokine IL-6 in mild to moderate AD. We predict that the novel anti-inflammatory agent ingested human recombinant interferon alpha (hrIFN-a) will modulate inflammation and inhibit the natural history of AD progression. If you are eligible, you will receive Aricept for 5 weeks (donezepil) and thereafter in addition to Aricept either placebo (inactive substance) or interferon alpha at 3,000 or 30,000 units every day for 12 months.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-02 MST

Cite this

APA
Anonymous. (n.d.). Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha. <em>National Center for Research Resources (NCRR)</em>. https://clinicaltrials.gov/study/NCT00031018
Vancouver
Anonymous. Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha. National Center for Research Resources (NCRR).
BibTeX
@misc{anonndPreven, title = {Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha}, author = {Anonymous}, journal = {National Center for Research Resources (NCRR)}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings